ClinicalTrials.gg
CompletedNCT02589665Updated Jun 17, 2020Results posted

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of Mirikizumab and Placebo in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 77 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
6th of 13
249 · median 172
Started
2015
the only one that year
Phase 2
2 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 6th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 2, and was the 1st registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The main purpose of this study is to test the hypothesis that treatment with mirikizumab is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • IL-23 antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have moderate to severe active UC as defined by a Mayo score of 6 to 12 with an endoscopic subscore ≥2 within 14 days before the first dose of study treatment (note: a partial Mayo score of at least 4 and other eligibility criteria must have been met before endoscopy is performed as a study procedure)
  • Have evidence of UC extending proximal to the rectum (≥15 centimeters [cm] of involved colon)
  • Up-to-date colorectal cancer surveillance (performed according to local standard), for subjects with family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor
  • Participants must either: be naive to biologic therapy (eg, tumor necrosis factor [TNF] antagonists or vedolizumab) and have at least 1 of the following: inadequate response or failure to tolerate current treatment with oral or intravenous or immunomodulators (6-mercaptopurine or azathioprine) or history of corticosteroid dependence (an inability to successfully taper corticosteroids without return of UC) OR have received treatment with 1 or more biologic agents (eg, TNF antagonists or vedolizumab) at doses approved for the treatment of UC with documented history of failure to respond to or tolerate such treatment

Exclusion criteria

Exclusion Criteria:

  • Have been diagnosed with indeterminate colitis, proctitis (distal disease involving the rectum only; less than 15 cm from the anal verge) or Crohn's Disease
  • Have had surgery for treatment of UC or are likely to require surgery for UC during the study
  • Have received any of the following for treatment of UC: cyclosporine or thalidomide within 30 days of screening, enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 30 days of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    50 mg Mirikizumab IV Q4W (Induction)

    50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.

    Drug: Mirikizumab

  • Experimental
    200 mg Mirikizumab IV Q4W (induction)

    200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.

    Drug: Mirikizumab

  • Experimental
    600 mg Mirikizumab IV Q4W (Induction)

    600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.

    Drug: Mirikizumab

  • Placebo comparator
    Placebo IV Q4W (Induction)

    Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.

    Drug: Placebo

  • Experimental
    200 mg Mirikizumab SC Q4W (Maintenance)

    Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.

    Drug: Mirikizumab

  • Experimental
    200 mg Mirikizumab SC Q12W (Maintenance)

    Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.

    Drug: Mirikizumab

  • Placebo comparator
    Placebo SC Q4W (Maintenance)

    Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.

    Drug: Placebo

  • Experimental
    600mg Mirikizumab IV Q4W Extension Open-Label

    Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.

    Drug: Mirikizumab

  • Experimental
    1000mg Mirikizumab IV Q4W Extension Open-Label

    Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.

    Drug: Mirikizumab

  • Experimental
    200mg Mirikizumab SC Q4W Extension Open-Label

    Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label

    Drug: Mirikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Induction Period: Percentage of Participants With Clinical Remission at Week 12

    Clinical remission at week 12 is a defined as achieving a 9-pt Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1, excluding Physician's Global Assessment (PGA). * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from 0 (normal) to 3 (severe disease). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.

    Time frame: Week 12

Secondary outcomes

  1. Induction Period: Percentage of Participants With Clinical Response at Week 12

    Clinical response at week 12 is defined as a decrease in the 9-point Mayo subscores (rectal bleeding, stool frequency and the endoscopic findings) inclusive of \>= 2 points and \>=35% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.

    Time frame: Week 12

  2. Induction Period: Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic score of 0 at Week 12. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.

    Time frame: Week 12

  3. Maintenance Period: Percentage of Participants With Endoscopic Remission at Week 52

    Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 at Week 52. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.

    Time frame: Week 52

  4. Induction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is a 32-item subject-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 12

  5. Induction Period: Change From Baseline to Week 12 in 36-Item Short Form Health Survey (SF-36)

    SF-36 Health Status Survey is a generic, health-related scale assessing participant's quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health. Domain scores: general health (range: 5-25); physical functioning (range: 10-30); role-physical (range: 4-8); role-emotional (range: 3-15); social functioning (range: 2-10); bodily pain (range: 2-12); vitality (range: 4-20); mental health (range: 5-25). Each raw scale score was converted to a scale score ranging from 0-100 points, with higher values representing a better outcome \[(Raw score) - min{raw score}\] / (max {raw score} - min{raw score}) x 100\]. LS Mean was calculated using Mixed effect Model Repeat Measurement (MMRM) model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 12

  6. Induction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score

    PGI-S is a 1-item subject-rated questionnaire designed to assess the subject's impression of their disease symptoms at baseline (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point scale in which a score of 1 indicates that the subject's symptom(s) are "normal," a score of 2 indicates that the subject feels "borderline ill," a score of 3 indicates that the subject feels "mildly ill," a score of 4 indicates that the subject(s) feel "moderately ill," and scores of 5, 6, and 7 indicate that the subject feels "markedly ill," "severely ill," and "extremely ill," respectively. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 12

  7. Induction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 12

    PGI-I scale is a subject-rated instrument designed to assess the subject's impression of change in their symptom(s) (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the subject's symptom(s) is "very much better," a score of 4 indicates that the subject's symptom(s) has experienced "no change," and a score of 7 indicates that the subject's symptom(s) is "very much worse."

    Time frame: Week 12

  8. Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab

    Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, tau) of Mirikizumab

    Time frame: Induction Period: Day (D) 1, D15 ± 2d, D29 ± 2d, D43 ± 2d, D57 ± 2d, D78-85; Maintenance Period: D85-92,D113± 7d,D141± 7d,D169± 7d,D225 ±7d,D281 ±7d,D337 ±7d,D393± 7d,D448± 7d,D504± 7d,D560± 7d,D616± 7d,D672± 7d,D728± 7d,D784± 7d,D840± 7d

  9. Induction Period: Percentage of Participants With Symptomatic Remission at Week 12

    Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore is based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). * Rectal Bleeding Subscore is based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

    Time frame: Week 12

  10. Maintenance Period: Percentage of Participants With Symptomatic Remission at Week 52

    Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore , based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore , based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore , based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to 3 (severe disease). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

    Time frame: Week 52

  11. Induction Period: Percentage of Participants With Endoscopic Improvement at Week 12

    Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

    Time frame: Week 12

  12. Maintenance Period: Percentage of Participants With Endoscopic Improvement at Week 52

    Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

    Time frame: Week 52

07

Results

Posted May 29, 2020

Participant flow

Induction Period
Participant flow — Induction Period
MilestoneInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension: 1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
Started63636261000000
Received at least one dose of study drug63636260000000
Completed60616057000000
Not completed3224000000
Withdrew: Did not receive drug0001000000
Withdrew: Adverse event3022000000
Withdrew: Withdrawal by subject0101000000
Withdrew: Protocol violation0100000000
Maintenance Period
Participant flow — Maintenance Period
MilestoneInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension: 1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
Started0000134746000
Completed0000000000
Not completed0000134746000
Withdrew: Rolled over to study amap (nct03519945)000074139000
Withdrew: Withdrawal by subject0000424000
Withdrew: Lack of efficacy0000210000
Withdrew: Adverse event0000002000
Withdrew: Lost to follow-up0000010000
Withdrew: Physician decision0000010000
Withdrew: Reason not collected0000011000
Induction Extension Period
Participant flow — Induction Extension Period
MilestoneInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension: 1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
Started000000032960
Completed000000030840
Not completed00000002120
Withdrew: Adverse event0000000040
Withdrew: Lack of efficacy0000000030
Withdrew: Withdrawal by subject0000000230
Withdrew: Physician decision0000000010
Withdrew: Reason not collected0000000010
Maintenance Extension Period
Participant flow — Maintenance Extension Period
MilestoneInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension: 1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
Started00000000068
Completed0000000000
Not completed00000000068
Withdrew: Rolled over to study amap (nct03519945)00000000057
Withdrew: Withdrawal by subject0000000004
Withdrew: Lack of efficacy0000000004
Withdrew: Adverse event0000000002
Withdrew: Non-responder0000000001

Outcome measures

PrimaryInduction Period: Percentage of Participants With Clinical Remission at Week 12

Clinical remission at week 12 is a defined as achieving a 9-pt Mayo subscore for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1, excluding Physician's Global Assessment (PGA). * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from 0 (normal) to 3 (severe disease). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Induction Period: Percentage of Participants With Clinical Remission at Week 12
percentage of participantsPlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Percentage of Participants With Clinical Remission at Week 124.8 (0.0 to 10.0)15.9 (6.8 to 24.9)22.6 (12.2 to 33.0)11.5 (3.5 to 19.5)
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Odds ratio (or): 2.93 · 95% CI 0.70 to 12.27
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Odds ratio (or): 7.22 · 95% CI 1.88 to 27.65
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Odds ratio (or): 3.61 · 95% CI 0.92 to 14.17
SecondaryInduction Period: Percentage of Participants With Clinical Response at Week 12

Clinical response at week 12 is defined as a decrease in the 9-point Mayo subscores (rectal bleeding, stool frequency and the endoscopic findings) inclusive of \>= 2 points and \>=35% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores: * Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The total score ranges from 0 to 9 points, with higher scores representing more severe disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Induction Period: Percentage of Participants With Clinical Response at Week 12
percentage of participantsPlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Percentage of Participants With Clinical Response at Week 1220.6 (10.6 to 30.6)41.3 (29.1 to 53.4)59.7 (47.5 to 71.9)49.2 (36.6 to 61.7)
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Odds ratio (or): 3.95 · 95% CI 1.73 to 8.98
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Odds ratio (or): 6.78 · 95% CI 2.94 to 15.63
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Odds ratio (or): 2.78 · 95% CI 1.23 to 6.29
SecondaryInduction Period: Percentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission at week 12 is defined as achieving a Mayo endoscopic score of 0 at Week 12. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Induction Period: Percentage of Participants With Endoscopic Remission at Week 12
percentage of participantsPlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Percentage of Participants With Endoscopic Remission at Week 121.6 (0.0 to 4.7)3.2 (0.0 to 7.5)3.2 (0.0 to 7.6)1.6 (0.0 to 4.8)
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Mantel Haenszel · p = 0.986
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Mantel Haenszel · p = 0.553
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Mantel Haenszel · p = 0.560
SecondaryMaintenance Period: Percentage of Participants With Endoscopic Remission at Week 52

Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 at Week 52. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); The total score ranges from 0 to 3 points, with higher scores representing more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Maintenance Period: Percentage of Participants With Endoscopic Remission at Week 52
percentage of participantsPlacebo SC Q4W200 mg Mirikizumab SC Q4W200 mg Mirikizumab SC Q12W
Maintenance Period: Percentage of Participants With Endoscopic Remission at Week 527.7 (0.0 to 22.2)14.9 (4.7 to 25.1)28.3 (15.2 to 41.3)
Statistical analysis
  • 200 mg Mirikizumab SC Q4W vs 200 mg Mirikizumab SC Q12W · Odds ratio (or): 2.29 · 95% CI 0.80 to 6.55
SecondaryInduction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is a 32-item subject-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function (Guyatt et al. 1989). Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Induction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
score on a scalePlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Change From Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score22.3 ± 4.4133.0 ± 4.5242.8 ± 4.4045.2 ± 4.54
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Mean difference (final values): 22.9 · 95% CI 11.0 to 34.9
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Mean difference (final values): 20.5 · 95% CI 8.7 to 32.3
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Mean difference (final values): 10.7 · 95% CI -1.0 to 22.5
SecondaryInduction Period: Change From Baseline to Week 12 in 36-Item Short Form Health Survey (SF-36)

SF-36 Health Status Survey is a generic, health-related scale assessing participant's quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health. Domain scores: general health (range: 5-25); physical functioning (range: 10-30); role-physical (range: 4-8); role-emotional (range: 3-15); social functioning (range: 2-10); bodily pain (range: 2-12); vitality (range: 4-20); mental health (range: 5-25). Each raw scale score was converted to a scale score ranging from 0-100 points, with higher values representing a better outcome \[(Raw score) - min{raw score}\] / (max {raw score} - min{raw score}) x 100\]. LS Mean was calculated using Mixed effect Model Repeat Measurement (MMRM) model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Induction Period: Change From Baseline to Week 12 in 36-Item Short Form Health Survey (SF-36)
score on a scalePlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Physical Component Score3.4 ± 0.836.2 ± 0.865.9 ± 0.836.9 ± 0.85
Mental Component Score3.2 ± 1.224.5 ± 1.266.8 ± 1.208.8 ± 1.25
Physical Functioning2.1 ± 0.763.7 ± 0.784.6 ± 0.746.2 ± 0.77
Role-Physical4.5 ± 1.197.5 ± 1.227.2 ± 1.178.0 ± 1.22
Bodily Pain3.7 ± 1.157.9 ± 1.188.9 ± 1.1410.0 ± 1.18
General Health3.1 ± 0.933.8 ± 0.964.3 ± 0.925.1 ± 0.96
Vitality3.3 ± 1.256.5 ± 1.287.5 ± 1.239.7 ± 1.28
Social Functioning6.5 ± 1.228.0 ± 1.269.4 ± 1.2111.6 ± 1.26
Role-Emotional3.0 ± 1.223.7 ± 1.265.5 ± 1.207.6 ± 1.25
Mental Health1.9 ± 1.183.7 ± 1.226.4 ± 1.177.6 ± 1.21
SecondaryInduction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score

PGI-S is a 1-item subject-rated questionnaire designed to assess the subject's impression of their disease symptoms at baseline (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point scale in which a score of 1 indicates that the subject's symptom(s) are "normal," a score of 2 indicates that the subject feels "borderline ill," a score of 3 indicates that the subject feels "mildly ill," a score of 4 indicates that the subject(s) feel "moderately ill," and scores of 5, 6, and 7 indicate that the subject feels "markedly ill," "severely ill," and "extremely ill," respectively. LS Mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + Geographical Region + Prior Biologic Therapy Group (N) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Induction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score
score on a scalePlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Change From Baseline to Week 12 in Patient's Global Impressions of Severity (PGI-S) Score-0.84 ± 0.19-1.43 ± 0.20-1.90 ± 0.18-1.74 ± 0.19
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Mean difference (final values): -0.90 · 95% CI -1.39 to -0.41
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Mean difference (final values): -1.06 · 95% CI -1.54 to -0.59
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Mean difference (final values): -0.59 · 95% CI -1.07 to -0.11
SecondaryInduction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 12

PGI-I scale is a subject-rated instrument designed to assess the subject's impression of change in their symptom(s) (Guy 1976; Yalcin and Bump 2003). Responses are graded on a 7-point Likert scale in which a score of 1 indicates that the subject's symptom(s) is "very much better," a score of 4 indicates that the subject's symptom(s) has experienced "no change," and a score of 7 indicates that the subject's symptom(s) is "very much worse."

Time frame:
Week 12
Reported as:
Mean · score on a scale
Induction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 12
score on a scalePlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Patient's Global Impressions of Improvement (PGI-I) Score at Week 123.37 ± 1.462.69 ± 1.312.39 ± 0.992.53 ± 1.16
SecondaryPharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab

Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, tau) of Mirikizumab

Time frame:
Induction Period: Day (D) 1, D15 ± 2d, D29 ± 2d, D43 ± 2d, D57 ± 2d, D78-85; Maintenance Period: D85-92,D113± 7d,D141± 7d,D169± 7d,D225 ±7d,D281 ±7d,D337 ±7d,D393± 7d,D448± 7d,D504± 7d,D560± 7d,D616± 7d,D672± 7d,D728± 7d,D784± 7d,D840± 7d
Reported as:
Geometric mean · Microgram*hour/milligram(ug*hr/ml)
Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab
Microgram*hour/milligram(ug*hr/ml)50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W200 mg Mirikizumab SC Q4W200 mg Mirikizumab SC Q12W
Pharmacokinetics (PK): Area Under the Concentration-Time Curve During Dosing Interval at Steady State (AUCss, Tau) of Mirikizumab3330 ± 42.510100 ± 35.024900 ± 36.63700 ± 41.51270 ± 42.3
SecondaryInduction Period: Percentage of Participants With Symptomatic Remission at Week 12

Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore is based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). * Rectal Bleeding Subscore is based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Induction Period: Percentage of Participants With Symptomatic Remission at Week 12
percentage of participantsPlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Percentage of Participants With Symptomatic Remission at Week 1220.6 (10.6 to 30.6)36.5 (24.6 to 48.4)58.1 (45.8 to 70.3)45.9 (33.4 to 58.4)
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Regression, Logistic · p = 0.003 · Odds ratio (or): 3.61 · 95% CI 1.57 to 8.31
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.54 · 95% CI 2.81 to 15.20
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Regression, Logistic · p = 0.054 · Odds ratio (or): 2.27 · 95% CI 0.98 to 5.22
SecondaryMaintenance Period: Percentage of Participants With Symptomatic Remission at Week 52

Symptomatic remission is defined as a stool frequency score of 0 or 1 and a rectal bleeding score of 0. * Stool Frequency Subscore , based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); * Rectal Bleeding Subscore , based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); * Endoscopy Subscore , based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration); * Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to 3 (severe disease). The total score ranges from 0 to 1 points, with higher scores representing more severe disease. The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Maintenance Period: Percentage of Participants With Symptomatic Remission at Week 52
Percentage of ParticipantsPlacebo SC Q4W200 mg Mirikizumab SC Q4W200 mg Mirikizumab SC Q12W
Maintenance Period: Percentage of Participants With Symptomatic Remission at Week 5253.8 (26.7 to 80.9)76.6 (64.5 to 88.7)65.2 (51.5 to 79.0)
Statistical analysis
  • 200 mg Mirikizumab SC Q4W vs 200 mg Mirikizumab SC Q12W · Regression, Logistic · p = 0.131 · Odds ratio (or): 0.48 · 95% CI 0.19 to 1.24
SecondaryInduction Period: Percentage of Participants With Endoscopic Improvement at Week 12

Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Induction Period: Percentage of Participants With Endoscopic Improvement at Week 12
percentage of participantsPlacebo IV Q4W50 mg Mirikizumab IV Q4W200 mg Mirikizumab IV Q4W600 mg Mirikizumab IV Q4W
Induction Period: Percentage of Participants With Endoscopic Improvement at Week 126.3 (0.3 to 12.4)23.8 (13.3 to 34.3)30.6 (19.2 to 42.1)13.1 (4.6 to 21.6)
Statistical analysis
  • Placebo IV Q4W vs 600 mg Mirikizumab IV Q4W · Regression, Logistic · p = 0.215 · Odds ratio (or): 2.25 · 95% CI 0.63 to 8.07
  • Placebo IV Q4W vs 200 mg Mirikizumab IV Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.70 · 95% CI 2.37 to 25.00
  • Placebo IV Q4W vs 50 mg Mirikizumab IV Q4W · Regression, Logistic · p = 0.012 · Odds ratio (or): 4.62 · 95% CI 1.41 to 15.14
SecondaryMaintenance Period: Percentage of Participants With Endoscopic Improvement at Week 52

Endoscopic Improvement defined as achieving an endoscopic findings subscore of 0 or 1. Endoscopy Subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The percentage of response is calculated by dividing number of participants in the specified category by number of participants with non-missing values multiplied by 100.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Maintenance Period: Percentage of Participants With Endoscopic Improvement at Week 52
Percentage of ParticipantsPlacebo SC Q4W200 mg Mirikizumab SC Q4W200 mg Mirikizumab SC Q12W
Maintenance Period: Percentage of Participants With Endoscopic Improvement at Week 5215.4 (0.0 to 35.0)57.4 (43.3 to 71.6)47.8 (33.4 to 62.3)
Statistical analysis
  • 200 mg Mirikizumab SC Q4W vs 200 mg Mirikizumab SC Q12W · Regression, Logistic · p = 0.428 · Odds ratio (or): 0.71 · 95% CI 0.31 to 1.65

Adverse events

Collected over Up To 39 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction: Placebo IV Q4W0/63 (0%)2/63 (3.2%)18/63 (28.6%)
Induction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W)0/63 (0%)0/63 (0%)14/63 (22.2%)
Induction: 200 mg Mirikizumab IV Q4W0/62 (0%)2/62 (3.2%)8/62 (12.9%)
Induction: 600 mg Mirikizumab IV Q4W0/60 (0%)3/60 (5%)14/60 (23.3%)
Maintenance: Placebo SC Q4W0/13 (0%)2/13 (15.4%)11/13 (84.6%)
Maintenance: 200 mg Mirikizumab SC Q4W0/47 (0%)2/47 (4.3%)27/47 (57.4%)
Maintenance: 200 mg Mirikizumab SC Q12W0/46 (0%)1/46 (2.2%)30/46 (65.2%)
Induction Extension: 600mg Mirikizumab IV Q4W0/32 (0%)1/32 (3.1%)9/32 (28.1%)
Induction Extension:1000mg Mirikizumab IV Q4W0/96 (0%)5/96 (5.2%)8/96 (8.3%)
Maintenance Extension: 200mg Mirikizumab SC Q4W0/68 (0%)3/68 (4.4%)30/68 (44.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W)Induction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension:1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
AppendicitisInfections and infestations0/630/630/620/601/130/470/460/320/960/68
Streptococcal bacteraemiaInfections and infestations0/630/630/620/601/130/470/460/320/960/68
Head injuryInjury, poisoning and procedural complications0/630/630/620/601/130/470/460/320/960/68
Breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/630/630/620/600/130/470/461/320/960/68
Colitis ulcerativeGastrointestinal disorders0/630/631/621/600/131/471/460/322/960/68
Clostridium difficile infectionInfections and infestations0/630/630/620/600/131/470/460/320/960/68
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/630/630/620/600/130/470/460/322/960/68
GastroenteritisInfections and infestations0/630/631/621/600/130/470/460/320/960/68
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/630/630/621/600/130/470/460/320/960/68
Large intestine perforationGastrointestinal disorders1/630/630/620/600/130/470/460/320/960/68
Most frequent other events
Showing 10 of 48
Most frequent other events
EventInduction: Placebo IV Q4WInduction: 50 mg Mirikizumab Administered Every 4 Weeks (Q4W)Induction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WMaintenance: Placebo SC Q4WMaintenance: 200 mg Mirikizumab SC Q4WMaintenance: 200 mg Mirikizumab SC Q12WInduction Extension: 600mg Mirikizumab IV Q4WInduction Extension:1000mg Mirikizumab IV Q4WMaintenance Extension: 200mg Mirikizumab SC Q4W
Colitis ulcerativeGastrointestinal disorders6/632/631/621/607/134/477/460/320/967/68
Upper respiratory tract infectionInfections and infestations0/630/630/620/603/135/473/460/320/966/68
Back painMusculoskeletal and connective tissue disorders0/630/630/620/603/131/473/460/320/966/68
NasopharyngitisInfections and infestations6/635/633/625/601/136/478/465/327/9614/68
Vaginal haemorrhageReproductive system and breast disorders0/270/250/250/221/50/200/240/120/330/25
NauseaGastrointestinal disorders4/632/632/623/602/133/470/460/320/960/68
FatigueGeneral disorders0/630/630/620/602/131/473/460/320/960/68
Injection site painGeneral disorders0/630/630/620/602/133/472/460/320/960/68
Herpes zosterInfections and infestations0/630/630/620/602/131/470/460/320/960/68
ArthralgiaMusculoskeletal and connective tissue disorders0/630/630/620/600/136/471/460/320/960/68

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Induction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WTotal
Mean42.62 ± 13.4741.83 ± 14.0643.35 ± 14.7542.44 ± 13.37142.56 ± 13.85
Sex: Female, Male
Sex: Female, Male(Participants)Induction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WTotal
Female27252523100
Male36383738149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WTotal
Hispanic or Latino03227
Not Hispanic or Latino60585954231
Unknown or Not Reported321511
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WTotal
American Indian or Alaska Native00000
Asian10513533
Native Hawaiian or Other Pacific Islander00000
Black or African American11507
White52574456209
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Induction: Placebo IV Q4WInduction: 50 mg Mirikizumab IV Q4WInduction: 200 mg Mirikizumab IV Q4WInduction: 600 mg Mirikizumab IV Q4WTotal
Hungary536418
Czechia10012
Japan8513531
United Kingdom22026
Moldova575724
Canada21036
Netherlands144211
Belgium473721
Denmark00011
Poland151412849
Georgia472114
Lithuania41319
Australia13127
United States119131750
08

Study locations

77 sites
  • Precision Research Institute, LLC
    Chula Vista, California 91910, United States
  • University of California - San Diego
    La Jolla, California 92093, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Borland Groover Clinic
    Jacksonville, Florida 32256 6004, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Delta Research Partners LLC
    Monroe, Louisiana 71201, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55446, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
  • Care Access Research - Salt Lake City
    Salt Lake City, Utah 84124, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, 2139, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fitzroy, 3065, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    South Brisbane, 4101, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloongabba, 4102, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ghent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Calgary, T2N 2T9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, t2n2z6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H1T 2M4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H3A 1A1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montréal, H3G 1A4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hradec Kralove, 50012, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hradec Králové, 50012, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 4 Kralove, 14059, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha 4, 140 21, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Praha 4, 14059, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha, 14021, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha, 17004, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Svendborg, 5700, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clichy, 92110, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier Cedex 5, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06202, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Priest en Jarez, 42270, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vandoeuvre Les Nancy, 54511, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tbilisi, 0112, Georgia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bekescsaba, 5600, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1125, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szeged, 6720, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szekszard, 7100, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vac, 2600, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bunkyo-ku, 113-8519, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Chuo-ku, 060-0033, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima-shi, 892-0846, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kamakura-shi, 247-0056, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Kasugai-shi, 487-0031, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kawasaki, 210-0013, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Mitaka, 181-8611, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Nishinomiya, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oita City, 870-0033, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka-City, 530-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saga-shi, 840-8571, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Sakura, 285-8741, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shinjuku-ku, 169-0073, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Takasaki, 370-0829, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Toyama, 930-8550, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toyota-shi, 470-1219, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Tsu-shi, 514-8507, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Yokohama, 220-0045, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaunas, LT-50009, Lithuania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vilnius, 08661, Lithuania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chisinau, MD2025, Moldova, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amsterdam, 1105 AZ, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elblag, 82-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Katowice, 40 660, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Krakow, 31009, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-582, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rzeszow, 35-068, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sopot, 81-756, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 03 580, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warszawa, 03-580, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 53 114, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wrocław, 53114, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020125, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oxford, OX3 9DU, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winchester, S022 5DG, United Kingdom
09

References and documents

Publications

  • Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Jan;20(1):105-115.e14. doi: 10.1016/j.cgh.2020.09.028. Epub 2020 Sep 18. PubMed 32950748 ↗
  • Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020 Feb;158(3):537-549.e10. doi: 10.1053/j.gastro.2019.08.043. Epub 2019 Sep 4. PubMed 31493397 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Dec 2017, 24 months.

Results were first posted in May 2020, 2 years 5 months after primary completion. A results delay was requested in Nov 2018.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 28, 2015
StartActual
Dec 9, 2015
Primary completionActual
Dec 19, 2017
CompletionActual
May 7, 2019
Results delay requested
Nov 30, 2018
Results first posted
May 29, 2020
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02589665
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Dec 9, 2015
Primary completion
Dec 19, 2017
Completion
May 7, 2019
Results posted
May 29, 2020
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion